EP4536119A1 - Gynaecological device for permanent tubal sterilization using a bendable radiofrequency applicator - Google Patents

Abstract

The invention relates to a single-use gynaecological device (1) for producing thermal lesions in the Fallopian tubes by application of radiofrequency in order to bring about permanent sterilization, said device (1) comprising an elongate tubular applicator (10) which extends along a longitudinal axis (XX') and is equipped with a manual gripping means (20) arranged near a proximal end (1a), and with an active segment, for emission of bipolar radiofrequency, arranged near a distal end (1b), said active segment for emission of bipolar radiofrequency being connected to a radiofrequency source (30), characterized in that the manual gripping means (20) has at least one manually movable mechanical bending actuator (50) for bending the distal end (1b) of the elongate tubular applicator (10), and a means (60) for blocking said bending once the latter has been determined with the aid of said mechanical bending actuator (50).

Description

Description

Title of the invention: Gynecological medical device for definitive tubal sterilization using a curved radiofrequency applicator

Technical field of the invention

The present invention relates to a single-use gynecological medical device intended to produce thermal lesions in the intra-myometrial part of the fallopian tubes by application of radiofrequency. This thermal injury is accompanied by tubal obstruction by thermofusion so as to create definitive tubal sterilization.

Prior art

[0002] Definitive medical tubal sterilization by action on the fallopian tubes has existed for many years and most often requires a surgical procedure: laparoscopic or hysteroscopic.

[0003] An extremely common method of female sterilization is the ligation of the tubes using titanium and silicone clips ("Filshie ® Clip" for example) which are closed around each tube, close to the tube. 'uterus. Traditionally, this is a surgical procedure performed in the operating room under general anesthesia. It has also become possible to ligate or clip the fallopian tubes as part of a minimally invasive surgical procedure: laparoscopy or laparoscopy. It consists of piercing the abdominal wall using a trocar (tubular element called a “trocar sleeve” or “laparoscopic cannula”). For this surgical procedure, two trocars are usually required, namely an umbilical trocar to introduce the laparoscope (camera) to provide visual feedback to the practitioner on the operation, and a medial suprapubic trocar to introduce a clamp applicator to position and tighten the clips. In case of exposure difficulties, another trocar can be introduced through the abdominal wall to allow the operator to better expose the tubes. In general, when the first trocar is positioned, the abdominal cavity is put under pressure (CO ₂ inflation) to distend the abdominal wall and allow the organs to be visualized and mobilized safely.

[0004] Laparoscopic surgery has several advantages over conventional surgery by transverse incision of the abdominal wall (laparotomy). Laparoscopic perforations, which are smaller than the incisions made during conventional operations, are less painful for the patient and allow for accelerated recovery and convalescence. Hospital stays are thus reduced to a minimum. At the same time, laparoscopic surgery takes less time and is less expensive than conventional surgery to perform the same procedure.

[0005] A major disadvantage of laparoscopic surgery is that it must always be performed in a hospital establishment in an operating room, even if most often it is an outpatient surgery. It cannot be performed in “office surgery” medical practices. Even if complications are rare, they expose the patient to the risks of general anesthesia and surgery (hematoma, infection, thromboembolic accident, etc.). Finally, the costs of convalescence and hospitalization are high for the community.

[0006] An alternative to this laparoscopic process was tubal sterilization by hysteroscopy (definitive and irreversible) using an innovative medical device (MD) developed by the company BAYER under the name ESSURE ®. The procedure involves placing a micro insert simultaneously in both fallopian tubes. This insert takes the form of a sort of spiral (expandable spring of approximately 4 centimeters in length) composed of a central part in stainless steel, active polyethylene terephthalate (PET) fibers inside the device allow the obstruction of the fallopian tube, an external spring composed of a nickel and titanium alloy (Nitinol) which allows the implant to be maintained in the tube and two platinum marker rings and silver solder -tin.

[0007] The device was placed at the level of the fallopian tubes by a gynecologist-obstetrician via the natural routes (vagina and cervix). Once in place, the implant deployed and matched the contours of the internal wall of the fallopian tube to attach to it. This technique was performed as “office surgery”, meaning it did not require general anesthesia. Its presence was responsible, in the 3 months after placement, for tissue fibrosis around the implant, responsible for permanent tubal obstruction. This reactive fibrosis was secondary to the reaction of the tubal tissues to the components of these implants. Tubal obstruction was validated by checking the correct positioning of the device in the tubes 3 months after installation, either by performing an x-ray of the abdomen without preparation or by a 3D ultrasound.

[0008] The simplicity of installation and the effectiveness of the device won over both professionals and patients. This technique quickly established itself as the new reference technique for definitive tubal sterilization.

[0009] However, this process, implemented since the end of the 1990s, was responsible in the immediate aftermath of mild to moderate pelvic pain, even cramps, vaginal bleeding and discomfort in the pelvis or back a few times. hours to a few days after the procedure. Some women might even experience headaches, nausea and/or vomiting, or dizziness and/or fainting. Some women, despite the absence of recognized allergies to the constituents of the implants, may have experienced chronicization or reappearance of these symptoms in the more or less long term.

[0010] According to the National College of French Gynecologists and Obstetricians (CNGOF), the effectiveness and safety of such a process/device were questioned in 2012 by the National Agency for the Safety of Medicines and Pharmaceutical Products. health (ANSM) and the Ministry of Health, after more than 10 years of use in France. This alert increased between 2015 and 2017 following notifications of adverse and potentially disabling events including gynecological symptoms or more general, varied and non-specific symptoms. In particular, pain, allergies or hypersensitivity reactions to different components, disorders intestinal disorders, neurosensory disorders, anxiety, depression, unusually severe fatigue, autoimmune pathologies, thyroid disorders, weakness of the lower limbs or even otolaryngological problems. Pelvic or general disorders often led patients to ask their doctor to consider removal (explantation) of the implanted device, which had also been able to migrate in an uncontrolled manner to other parts of the human body in certain exceptional cases also involving the safety of the positioning technique of these implants. This procedure was then performed under general anesthesia, by laparoscopy. After removal of the implants concerned, patients regained a quality of life similar to before their installation.

[0011] Thus, women presenting symptoms such as those described above should consult their doctor so as not to overlook a possible underlying iatrogenic pathology. In the absence of a precise diagnosis, the benefit of removal had to be considered between the woman concerned and the doctor.

[0012] Finally, this device was withdrawn from sale in France on September 18, 2017 by decision of the Minister of Solidarity and Health, then at the global level.

[0013] Different alternatives to surgical ligation of the tubes or to the ESSURE ® process described above exist and in particular use localized radiofrequency treatment to cause thermal lesions of the tissues at the entrance to the tubes in order to seal them to prevent fertilization of eggs by a sperm in the tubes.

The so-called thermofusion method of the tubes makes it possible to sterilize women by blocking the lumen of the tubes leading to the uterus. The thermal effect is accompanied by an alteration of the tubal ciliary epithelium and a contraction of the peri-tubal muscles (myometrium) and is responsible in a few days to a few weeks for a thermofusion of the tubal mucosa, responsible for permanent tubal obstruction.

[0015] Thus, patent US4057063A describes a device for sterilizing women by transuterine coagulation of the tubes comprising a high frequency generator and a probe connected thereto and which includes an active electrode. The invention described in this document aims to provide a device for transuterine coagulation of the tubes by means of which sterilization can be carried out very quickly and precisely without using a hysteroscope and therefore without anesthesia (local or general). For this purpose, the device described is characterized in that the probe is formed by a flexible catheter comprising at one end a metal portion which forms the active electrode and which is electrically connected to a connection provided near the other end of the catheter.

[0016] Patent US3840016 relates to a bipolar electrocoagulation electrode for intrauterine sterilization of the fallopian tubes by means of limited thermal radiation making it possible to cauterize only the portion of tissue to be obstructed, without damaging the surrounding tissues. To enable the correct positioning of the catheter in the fallopian tubes, for this purpose he uses a hysteroscope consisting of an optic connected to a camera and a tubular rod comprising an operating channel to introduce the radiofrequency applicator under control of view. The latter is made up of an insulated conductor whose distal end which projects from the hysteroscope includes a bipolar electrode (section emitting heat placed between two insulated sections). This heat destroys the tissues of the fallopian tube locally and over a short length and thickness, causing an inflammatory response in these tissues which creates local scarring responsible for the fusion of the walls of the fallopian tube. This progressive healing (a few weeks) then blocks said fallopian tube and thus causes definitive and irreversible sterilization of the patient.

[0017] Patent US5122137 relates to a radiofrequency medical device for heating the tissues of a patient in order to generate thermofusion (cauterization) of the latter, in particular in the intra-myometrial portion of the fallopian tubes. For this purpose, the device comprises several radio frequency conductors between which a radio frequency current circulates for cauterization fabrics. At least one of the conductors is a thermally conductive electrode that focuses radiofrequency current in a local region of tissue with which the electrode is in contact. A temperature sensor is carried by and is in thermally conductive relationship with the thermally conductive electrode. The temperature sensor positioned at the distal end of the electrode detects the temperature of the electrode and thus indirectly detects the temperature of the tissue in contact with the electrode. Finally, the sensor is connected by a feedback line to a control circuit which automatically modulates the power of the radio frequency applied to the electrode based on the feedback signal received by the temperature sensor. The principle of radiofrequency treatment can be used for the percutaneous treatment of liver metastases or for the transrectal treatment of prostate tumors, for the percutaneous treatment of varicose veins of the lower limbs according to the same principle of thermofusion or in gynecology for the percutaneous treatment of uterine fibroids. . In this fallopian tube application, instead of ligation, in which an abdominal incision is usually made to access the fallopian tubes, the device is inserted transvaginally into the uterus and then into the fallopian tube at the end. using a hysteroscope to heat the wall of the latter to a controlled temperature, thus causing an injury to the fallopian tube, a local inflammatory response, causing local scarring of the tissues responsible for the obstruction of said fallopian tube and causing permanent and irreversible sterilization of the patient.

[0018] Document US5303719 describes a surgical instrument intended to be used in a female sterilization operation comprising an elongated endoscope, also called a hysteroscope, provided with an operating channel through which an elongated flexible endoscopic surgical instrument is inserted. In a female sterilization procedure, the endoscope is inserted through the patient's vagina, cervix and uterus to the fallopian tube. It thus allows you to visualize the ostiums of the fallopian tubes (openings where the fallopian tubes enter the uterine cavity). The endoscope includes a guide for this purpose optical fiber illumination operably connected to a cold light source, a fiber optic image guide operably connected to an eyepiece or video monitor, and an auxiliary conduit extending longitudinally and connectable to tubing suction or a vacuum generator and an auxiliary conduit, also called working channel, allowing the introduction of the radiofrequency medical device. The surgical instrument is provided at a distal end with an active operating component for destroying the cells of the tubal ciliated epithelium, along an internal surface of the fallopian tube. The surgical instrument and/or endoscope are manipulated from outside the patient to move the operating component sufficiently close to the tubal ostium and allow introduction of the distal end of the radiofrequency probe (seat of the conductor of radiofrequency) in the intra-myometrial part of the fallopian tube. The operating component is operatively connected, at a proximal end of the surgical instrument, to an energy source which provides the operating component with the energy necessary for the destruction of organic tissues thanks to the energy delivered by the radio frequency source, for example in the form of a laser beam. The energy emitted by the source is transmitted along the fiber at such power that it partially destroys a layer of tissue along an inner surface of the entrance to the fallopian tube. The energy of the beam is controlled by the generator so that the diffusion of heat is limited around the bipolar electrode (cauterization zone). Likewise, the portion of the surgical instrument introduced into the tube is controlled, thus limiting the risk of tearing or perforation of the tube. As a result, the outer surface of the proboscis is kept intact. Alternatively, the instrument includes a tubular member and an electrical wire extending longitudinally through the tubular member from a source of electrical voltage at a proximal end of the tubular member. A cautery contact is operably connected to the wire at the distal end of the instrument. During traction of the tubular member in a proximal direction through the fallopian tube, the source electrical is operatively connected to the contact to transmit a cauterizing current to the inner surface of the fallopian tube, thereby destroying the cells of the tubal epithelium to allow the adhesion of this layer to itself and being responsible for the obstruction of the entrance to the tube which results in permanent and irreversible sterilization of the patient.

[0019] Patent US4700701 relates to a device for sterilizing the fallopian tubes comprising a catheter having a free working end and an opposite control end. The catheter includes an outer sleeve and a concentric inner core. A thermoelectric cautery is mounted on the free end of the catheter and is electrically powered by a Peltier cell consisting of a bimetallic structure formed of a hollow cylindrical copper substrate. Insulated electrical wires are electrically coupled to the Peltier cell and extend inside the catheter to a suitable electrical power source (preferably a direct current source) through a current regulator and a switch. The device works by cryo-cauterization, for example at -40° C, so as to destroy part of the epithelium of the fallopian tube placed in contact with the surface of the Peltier cell. The next step is to activate the generator using a “switch” positioned on the handle of the instrument. Thermal injury to said tissue responds by causing intense inflammation and scarring of the tissue. The end result is the replacement of the tubal epithelium and muscle tissue fibers exposed to cauterization with scar tissue, resulting in occlusion of the tube (where there was a hollow tube, there is now a solid column of fibrous tissue) causing the definitive and irreversible sterilization of the patient.

[0020] Patent US5095917 relates to an irreversible sterilization method which combines the destruction of the epithelium of the fallopian tubes by hyperthermia with the insertion of a biodegradable plug. As in the previous paper, the destruction of the mucosa causes an inflammatory reaction and the plug serves as a substrate to initiate the occlusion process. More precisely, the method comprises the steps of destroying a superficial layer of the utero-tubal junction and inserting means for promoting the growth of scar tissue at said point of destruction of said utero-tubal junction. The sterilization instrument used includes a hollow tube containing one or more caps of biodegradable material which may or may not contain a drug such as tetracycline hydrochloride to delay breakdown of the initial clot and enhance scarification. The hollow tube is also equipped externally with copper wiring intended to be connected to a high frequency bipolar current generator via electrical cables. In operation, a bipolar coagulation current of approximately 5 watts for a duration of between 5 and 15 seconds is sufficient to produce irreversible but shallow thermal damage to the tubal epithelium. After bipolar coagulation of the utero-tubal junction, a piston is activated and the instrument is simultaneously withdrawn slightly, which has the effect of releasing a plug which will then be at the exact level of the destroyed mucosa of the utero-tubal junction . The application of bipolar electrical energy causes an immediate inflammatory reaction. Part of this reaction is "edema", which is swelling of the tissues. This natural mechanism keeps the cork in its position. The inflammatory cells leave the vessels and then colonize the damaged tissue. They first work to seal the area and then, with other cells, they repair the injury. The proliferation of fibroblasts (i.e. cells that form connective tissue) is part of this process. This proliferation process can be enhanced by certain medications, such as tetracycline hydrochloride, contained in the cap. Thanks to the presence of the plug, the fibroblasts will not only colonize the damaged tissue, but also the plug. Other cells, such as macrophages, will "clean" the area and help digest the material the plug is made of. After a period of 3 to 6 weeks, the cells gradually disappear and leave behind a dense structure of fibers called scar tissue, which will also include the area where the plug has been inserted. This process therefore results in irreversible occlusion of the tubal lumen, thus rendering the patient sterile.

[0021] Finally, patent FR2748648 describes an apparatus and a method for transcervical sterilization and embolization using a catheter, and more particularly a temperature-controlled bipolar radiofrequency catheter, as well as its use to cause thermal lesions in the fallopian tubes. The transcervical sterilization apparatus includes an elongated catheter having a distal end and a connector on the opposite end having wires for connection to an electrosurgical generator that provides radiofrequency energy in the amount can be controlled. At least two bipolar electrodes, located around the distal end of the catheter, are spaced apart from each other. A temperature (variation) sensor determines the state of the transmural formation of the thermal lesion generated between each of the bipolar electrodes to transmit a signal to the electro-surgical generator, during monitoring, in order to control the application of radiofrequency energy to the inner wall of the fallopian tube.

[0022] All of these devices and methods, however, still have numerous drawbacks. They are particularly unsuitable for treating both tubes quickly, precisely and safely. They are not sufficiently ergonomic and easy to handle to optimize and reduce the duration of the intervention.

[0023] At present, there are no alternatives to hysteroscopic tubal ligation. Patients are therefore again offered laparoscopy to perform this tubal ligation technique. This represents a step backwards of more than twenty years in patient care.

Presentation of the invention

[0024] The present invention aims to remedy these drawbacks with a completely innovative approach to propose a solution that is simple to produce, easy to use, can be handled by a single person, is very safe, fast, efficient, can be manufactured in large quantities and relatively inexpensively. expensive and above all leaving no foreign bodies in the patient's body.

To this end, according to a first aspect, the present invention relates to a single-use gynecological medical device intended to produce thermal lesions in the fallopian tubes by application of bipolar radiofrequency to create definitive tubal sterilization, said device comprising a slender tubular applicator made of flexible material extending along a longitudinal axis and equipped with a handle-type manual gripping means disposed near a proximal end and an active bipolar radio frequency emission segment disposed nearby of a distal end, said active radio frequency emission segment being connected to a radio frequency source, characterized in that the manual gripping means further comprises at least:

- a manually movable mechanical bending actuator to bend the distal end of the slender tubular applicator, and

- means for blocking said curvature once it has been determined using said mechanical curvature actuator.

The device is intended to be used using an operating hysteroscope having an operating channel, the curvature takes place only at the exit of the hysteroscope into the uterine cavity.

[0027] Thanks to this controlled curvature, the solution of the present invention allows ideal introduction and positioning of the device in the entrance to the Fallopian tube (intra-myometrial portion), and in particular of its active emission zone of radiofrequency, and the possibility, thanks to the means of blocking the curvature of the applicator, of positioning the device in the second fallopian tube in an extremely rapid, precise and efficient manner to carry out its occlusion, all without having to do new potentially tedious adjustments of said curvature of the applicator

[0028] The invention is implemented according to the embodiments and variants set out below, which are to be considered individually or according to any technically effective combination. Advantageously, the tubular applicator comprises a bendable zone having a length of between approximately 2 and 10 centimeters from its distal end, preferably between approximately 4 and 8 centimeters.

[0030] This solution makes it possible to have a wide possibility of curvature on the one hand (radius of curvature) and to be able to best adapt the positioning of the active radiofrequency emission zone according to the morphology of the fallopian tube.

Preferably, the maximum angle of curvature formed between the longitudinal axis of the elongated tubular applicator and a tangent to its distal end is between approximately 30° and 90°.

[0032] This solution makes it possible to vary the curvature of the distal end of the device so that it adapts to the maximum possible cases encountered depending on the constraints of introduction of the device, the shape of the uterine cavity and of the entrance of the treated fallopian tubes and the practice of the specialized doctor who may prefer to choose one curvature rather than another.

[0033] According to a preferred embodiment of the present invention, the curvature actuator is a rotary wheel. This rotary wheel can be notched or not. The advantage of this notching is the maintenance of the angulation to facilitate contralateral treatment.

[0034] This very ergonomic solution is simple to implement in the handle, easy to use, precise and compact. It adapts to the usual practice of specialized doctors

[0035] In particular, the curvature actuator is a traction wheel that can be turned in two opposite directions of rotation around a pivot.

[0036] This solution is particularly compact and intuitive in its use.

[0037] According to a complementary aspect, the elongated tubular applicator contains at least one cable fixed on the one hand in the immediate vicinity of its distal end and on the other hand to the traction wheel, said cable being able to slide over a distance of a few millimeters inside the elongated tubular applicator, rotation in one direction of said traction wheel causing traction of said cable resulting in a curvature in a first direction of the distal end of the elongated tubular applicator as the wheel is turned, and rotation in the opposite direction of said traction wheel causing a traction of said cable resulting in a curvature in a second opposite direction of the distal end of the elongated tubular applicator as said wheel is rotated

[0038] This solution is particularly compact, since it is completely integrated into the tubular applicator, efficient and rapid, thanks to the direct and immediate action of the wheel on the cable, and guarantees optimal hygiene conditions since the curvature of the distal end of the device is controlled at its proximal end, located ex vivo.

[0039] The ergonomics of this solution allows it to be used with one hand.

[0040] According to a variant embodiment, the elongated tubular applicator contains at least two identical parallel cables fixed on the one hand in the immediate vicinity of its distal end and on the other hand at two opposite fixing points of the traction wheel , the cables being able to slide over a distance of a few millimeters inside the elongated tubular applicator, the rotation in one direction of said traction wheel causing traction of a first cable resulting in a curvature in a first direction of the distal end of the elongated tubular applicator as the wheel is rotated, and the rotation in the opposite direction of said traction wheel causing traction of the second cable resulting in a curvature in a second opposite direction of the the distal end of the elongated tubular applicator as said wheel is rotated.

[0041] This solution with double parallel cables allows more precise control of the curvature of the device and the responsiveness of its control.

[0042] Preferably, the curvature blocking means is a press button linked to the curvature actuator.

[0043] This solution is simple to implement, intuitive in terms of operation, very technically reliable and clinically proven. [0044] According to a particularly interesting aspect of the present invention, the elongated tubular applicator comprises, from its distal end, an active radiofrequency emission segment measuring between approximately 4 and 10 millimeters and preferably between approximately 6 and 8 millimeters.

[0045] This solution allows effective heat treatment of the fallopian tube which does not require extremely precise placement (below a millimeter) of the device since the active segment makes it possible to obtain the expected result of thermal lesions by radiofrequency .

[0046] Preferably, the elongated tubular applicator is crossed longitudinally by at least two separate conductive filaments respectively forming at their distal ends two radiofrequency electrodes spaced axially from each other and arranged in the active emission segment radio frequency. The electrode is called bipolar, thus providing maximum safety for the procedure.

[0047] This bipolar solution makes it possible to optimize the heat treatment of the epithelium of the fallopian tubes while guaranteeing maximum safety of the procedure for the patient.

Advantageously, each radiofrequency electrode has an axial length of between approximately 2 and 4 millimeters and preferably approximately equal to 3 millimeters.

[0049] Additionally, an electrical insulating segment is placed between the two radio frequency electrodes.

[0050] This solution makes it possible to limit the diffusion of the thermal effect in the vicinity of the electrode, thus producing a roughly “olivary” thermal diffusion around said electrode.

[0051] In particular, the insulating segment has an axial length approximately equal to 1 millimeter.

[0052] According to another aspect of the present invention, the distal end of the elongated tubular applicator comprises an atraumatic round tip measuring between approximately 1 and 2 millimeters in length. This tip is also insulating and thus prevents the distal diffusion of the thermal effect, thereby reducing the risk of collateral tissue damage. [0053] This solution allows the practitioner to position the device more easily in the desired area, without risking damage to the tissues (vagina, uterus, tubes).

According to another characteristic, the tubular applicator includes a mark opaque to X-rays and/or ultrasound placed upstream of the active radiofrequency emission segment.

[0055] This solution makes it possible to remotely monitor the introduction and progression of the device into the uterus then into the proximal part of the tubes and to verify the exact positioning of the active radiofrequency emission zone in order to carry out a thermal treatment on as precise and efficient as possible. This option is naturally only used in the case of anatomical variations and would justify carrying out the procedure under image intensifier or under ultrasound control.

According to a particular embodiment of the present invention, the manual gripping means is equipped with an indicator light indicating the operation of the radio frequency source.

[0057] This solution allows the practitioner to know exactly when the radiofrequency emission occurs in order to control in particular the duration of exposure.

[0058] For a similar purpose, the manual gripping means is equipped with an activation/deactivation button (“switch”) of the radio frequency source.

[0059] According to an advantageous characteristic of the present invention, the manual gripping means contains the radio frequency source and a removable battery for powering the radio frequency source. This solution therefore eliminates the need for an external RF generator.

[0060] This solution makes it possible to offer the practitioner equipment that is completely autonomous, compact and easy to handle.

[0061] According to another aspect of the present invention, the device further comprises a stop means fixing the longitudinal position of the active radiofrequency emission segment once the distal end of the tubular applicator implanted in the fallopian tube to the desired position. [0062] This solution guarantees effective and very precise positioning of the active radiofrequency emission zone, which prevents the practitioner from having to try again several times or fumbling around.

[0063] In particular, the stop means is an inflatable balloon mounted around the tubular applicator.

[0064] This solution allows rapid positioning without any risk of causing injury by too much (too deep) introduction of the applicator into the fallopian tube.

[0065] For the same reasons, and according to a variant embodiment, the stop means is a “stent” mounted in a substantially cylindrical sheath surrounding the tubular applicator, said stent being deployable like an umbrella to form a cone narrowing as one approaches the active radio frequency emission segment.

According to a final variant, the stop means is a localized annular thickening of the insulating sheath of the applicator with a width of approximately 1 to 2 mm for a thickness of approximately 0.5 mm.

Brief description of the figures

[0067] Other advantages, aims and characteristics of the present invention emerge from the description which follows, given for explanatory and in no way limiting purposes, with reference to the appended drawings, in which:

[0068] [Fig. 1] Figure 1 is a schematic view illustrating a first embodiment of a single-use gynecological medical device in accordance with the present invention and intended to produce thermal lesions in the fallopian tubes by application of radiofrequency,

[0069] [Fig. 2] Figure 2 is a view and a detailed view of a distal end of a slender tubular applicator of the medical device of Figure 1,

[0070] [Fig. 3] Figure 3 is a view of a first possible configuration of said distal end of Figure 2,

[0071] [Fig. 4] Figure 4 is a view of a second possible position configuration of said distal end of Figure 2, [0072] [Fig. 5] Figure 5 is a view of a third possible configuration of said distal end of Figure 2,

[0073] [Fig. 6] Figure 6 is a perspective view of a handling handle of the medical device of the present invention,

[0074] [Fig. 7] Figure 7 is an exploded view of Figure 6,

[0075] [Fig. 8] Figure 8 is a longitudinal sectional view of the handle of Figures 6 and 7,

[0076] [Fig. 9] Figure 9 is a detailed sectional view of the distal end of the elongated tubular applicator of the medical device of the present invention,

[0077] [Fig. 10] Figure 10 is a view similar to Figure 9 but in which an active segment of the distal end is in operation,

[0078] [Fig. 11] Figure 11 is a view illustrating the operation of the device according to the present invention,

[0079] [Fig. 12] Figure 12 is a sectional view of a part of the human body of a woman in which the device is shown in use,

[0080] [Fig. 13] Figure 5 is seen similar to Figure 13 in another step of use,

[0081] [Fig. 14] Figure 14 is a variant embodiment of Figure 1 comprising an integrated battery,

[0082] [Fig. 15] Figure 15 is a detailed view of the distal end of the device provided with a radially inflatable balloon,

[0083] [Fig. 16] Figure 16 is a view of an alternative embodiment of Figure 14 in which the balloon is replaced by a radially expandable stent, and

[0084] [Fig. 17] Figure 17 is a view similar to Figure 16 in which the stent is expanded radially.

Description of embodiments

[0085] A single-use gynecological medical device 1 according to the present invention is shown in Figure 1 in its inactive state before use in the human body of a woman. [0086] This gynecological medical device 1, intended to produce thermal lesions in the fallopian tubes by application of radiofrequency in order to create definitive sterilization, generally comprises:

- a slender tubular applicator 10 that is essentially solid (this is not a hollow catheter for injecting a product) extending over approximately 400 millimeters along a longitudinal axis XX' and made of a flexible biocompatible material,

- a manual gripping means 20, of the ergonomic handling handle type formed of two plastic half-shells, arranged at a proximal end la of the elongated tubular applicator 10, and

- a source 30 of bipolar radio frequency (for example 460khz at 5W), external in the present case (see Figure 14 for a fully integrated internal solution), connected to said handling handle 20 using for example a cable 25 of known type, and

[0087] A hysteroscope 80 having an operating channel inside which it is planned to insert the elongated tubular applicator 10.

The assembly thus formed is particularly compact, light and easy to handle.

[0089] The elongated tubular applicator 10 comprises, at a distal end 1b of the device 1, an active radio frequency emission segment 40 connected to the radio frequency source 30 and which will be described in more detail in relation to the Figures 9 and 10. Typically, the active radio frequency emission segment 40 measures axially approximately 6 to 8 millimeters, for example approximately 7 millimeters.

[0090] We actually mean by “distal end 1b” an entire zone starting from an atraumatic rounded tip 11 of the slender tubular applicator 10 and having a length (measured in the direction of the handle 20) of between approximately 2 and 10 centimeters, preferably between approximately 4 and 8 centimeters.

[0091] The atraumatic tip 11 measures axially approximately 1 millimeter in length. This tip has two objectives, namely to facilitate access to the operating site (non-traumatic passage of the applicator into the osmium tubal by the practitioner and prevent the diffusion of the thermal effect beyond a certain point, the thermal effect occurring only between the two electrodes (described later) in an olive shape.

[0092] As can be seen in Figure 2, the elongated tubular applicator 10 is initially rectilinear in a rest position before introduction into the human body. However, it is made of a material and has an external diameter such, approximately 1 and 5 millimeters, that its distal end 1b can curve over a distance of several centimeters from the rounded end 11 using a mechanical actuator curve 50 movable manually by a practitioner. A means 60, of the push button type, is also provided for blocking said curvature once it has been determined using the mechanical curvature actuator 50 and will be described in more detail in relation to Figures 6 to 8.

[0093] As is apparent from Figures 3 to 5, due to the flexibility of the elongated tubular applicator 10, the distal end 1b can take, in use and thanks to the mechanical curvature actuator 50, different curvatures (defined by their respective radii of curvature) and form an angle a, defined between the axis XX' and the tangent T at the distal end 1b, between approximately 30° and 90° depending on the configuration and conditions of use of the gynecological medical device 1.

[0094] Obtaining this curvature/angle a thus results both from the flexible structure of the tubular applicator 10, particularly at its distal end, and from the mechanical curving means described 50 ci - After.

[0095] Thus, the mechanical curving means 50, as shown in Figures 6 to 8, comprises a movable part integrated into the handling handle 50, namely a rotary tension wheel 51 mounted to rotate around a pivot 55 according to a certain angular range (a few degrees on either side of an inactive central position called “rest”). For this purpose, the tension wheel 51 has two lateral lugs 52 (left) and 53 (right) to facilitate its manual manipulation using one hand (for example with the thumb and index finger). Small notches 54 (parallel grooves) can be provided on the lugs lateral 52 and 53 to improve their grip (better grip thanks to this ribbed “grip” type texture) and make the practitioner's gesture more precise, faster and more efficient.

[0096] The handling handle 20 also includes a trigger switch type switch button 56 (usable for example with the practitioner's thumb) to start or stop the radio frequency source 30, as well as an indicator light 57 (of the type LED for example) serving as an indication light that the radiofrequency source 30 is active when the medical device 1 is used.

[0097] As can be seen in Figure 7, two cables 58 (on the left) and 59 (on the right), for example metallic (composite materials, for example based on carbon fiber or Kevlar, are possible for their lightness and their solidity) are fixed to the tension wheel 51, on either side of its pivot 55, and pass through almost the entirety of the tubular applicator 10 to be fixed at respective points 58b and 59b at the level of the distal end 1b of the medical device 1.

[0098] Thus, as will be described later in more detail in relation to Figures 12 and 13, the fact for the practitioner of turning the tension wheel 51 in one direction (for example clockwise when look at the handle 20 from above) by pushing the left lug 52 with your thumb (and incidentally by pulling the right lug 53 with your index finger) will exert traction on the right cable 59, then causing the progressive curvature from the distal end 1b of the tubular applicator towards the left as the wheel 51 is turned.

[0099] Rotation of the tension wheel 51 in the opposite direction (counterclockwise direction) by pushing on the right pin 53 with the index finger (and incidentally by pulling the left pin 52 with the thumb) will exert traction on the left cable 58 and cause the progressive curvature of the distal end 1b of the elongated tubular applicator 10 as the wheel 51 is turned.

[00100] The two cables 58 and 59 for curving by tension are preferably mounted sliding axially inside the material forming the elongated tubular applicator 10, while being fixed close the atraumatic tip 11 at points 58b and 59b so that the traction effect causing the curvature can occur.

[00101] In the right or left abutment position of the lugs 52 and 53 against the half-shells of the handle 20, the curvature of the distal end 1b of the elongated tubular applicator 10 is maximum.

[00102] As is visible in Figures 8 and 9, the distal end 1b of the tubular applicator has several distinct zones following each other axially starting from the atraumatic tip 11.

[00103] More precisely, an implantation zone 12 of the fixing points 58b and 59b of the cables 58 and 59 for curving by tension is provided and positioned as close as possible to the atraumatic tip 11, this so as to optimize the curvature of the elongated tubular applicator 10. Indeed, during rotation in one direction or the other of the tension wheel 51 by the practitioner, the cables 58 and 59 will exert their traction force as far as possible from the handling handle 20, which will optimize the formation of the radius of curvature of the elongated tubular applicator 10.

[00104] Following this implantation zone 12 measuring axially approximately 2 millimeters in length, there is the active segment 40 which firstly comprises a first electrode zone 13 measuring axially approximately 3 millimeters in length. It is in this first electrode zone 13 that a first fixing point 14b of a first copper filament 14 (left filament) is located, connected to the radio frequency source 30 via the handling handle 20. This first electrical filament 14 thus passes through the elongated tubular applicator 10 and extends, inside the latter, from its connection inside the handling handle 20 to its attachment point 14b.

[00105] Following this first electrode zone 13, an insulating segment 15, measuring axially approximately 1 millimeter in length, is provided. This segment 15 makes it possible to isolate the first electrode zone 13 from a second electrode zone 16 measuring axially approximately 3 millimeters in length. It is in this second electrode zone 16 that a second attachment point 17b is located for a second copper filament 17 (right filament) also connected to the radio frequency source 30 via the handling handle 20 This second filament electric 17 thus passes through the elongated tubular applicator 10 and extends, inside the latter, from its connection inside the handling handle 20 to its second attachment point 17b.

[00106] The two copper electrical filaments 14 and 17 are electrically isolated from each other. The active segment 40 thus measures axially approximately 7 millimeters in length.

[00107] Finally, a radio-opaque marker 18 measuring axially approximately 4 millimeters in length is provided upstream of the second electrode zone 16, at the entrance to the active segment 40. Markers 19 of black color are also represented ( see figure 10) every centimeter on the outside of the slender tubular applicator 10, over an axial distance of approximately 5 centimeters.

[00108] Figure 10 illustrates the operation of the medical device 1 when the radiofrequency source is turned on to send its bipolar signal into the active segment 40.

[00109] The principle of bipolar radiofrequency (RF) is to generate, by ionic agitation, a heat source leading to the controlled thermoablation of tissues above 60° C. The sealing of the tubal structure is obtained by shrinkage of tissues as a consequence of the destruction of their collagenous (helical) structure. The thermal effect of bipolar radiofrequency on a reduced tubular space with a small internal diameter (< 15 mm), such as a fallopian tube, results in its permanent obstruction. As heat dispersion remains limited to the confines of the electrodes, the risk of collateral damage to surrounding anatomical structures is almost zero.

[00110] Figure 11 shows how the practitioner can, in a simple, effective, precise and rapid manner, modify the curvature of the distal end 1b of the elongated tubular applicator 10 by a simple manual action on the rotary notched tension button 51 of the ergonomic handling handle 20. Depending on the fallopian tube that he wishes to treat first, he will bend more or less (between approximately 30° and 90° as seen previously) the distal end 1b of the slender tubular applicator 10 to the right or to the left. [00111] Figures 12 and 13 illustrate the practical use of the medical device 1 of the present invention once the latter has been implanted inside the uterus U of a woman to make her sterile, using in particular of an operating hysteroscope 80 having an operating channel in which the elongated tubular applicator 10 is inserted and slides longitudinally, it being understood that the curvature of the latter is only imposed on the latter at the exit from said hysteroscope.

[00112] In the present case, the curvature of the distal end 1b of the elongated tubular applicator 10 is oriented towards the left using the notched button 51, which indicates that the practitioner will perform his gynecological medical procedure on the left fallopian tube TFG (hysteroscope 80 inclined from right to left from its proximal end, as in Figure 12).

[00113] Thus, once the medical device 1 is correctly positioned and the active segment 40 placed at the desired location in the entrance (intramyometrial portion) of the TGF fallopian tube (the radio-opaque marker 18 and/or the graduations 19 can help the practitioner in this positioning), the practitioner blocks this curvature by pressing the pressure button 60, which prevents any untimely rotation of the tension wheel 51, and therefore any change in curvature of the end distal 1b. The practitioner can then trigger the bipolar radio frequency source 30 by pressing the switch button 56 to send an electric current into the copper filaments 14 and 17. This has the effect of locally creating (olive shape), at the level of the active segment 40, an increase in temperature (>60° C) which will cause destruction by thermal effect (burning) of the mucosal tissues over a small thickness. The indicator light 57 remains lit throughout this phase to indicate to the practitioner that the bipolar radio frequency source 30 is active.

[00114] Once the practitioner has judged that the thermal effect has lasted long enough and that it has been effective enough, he then releases the switch button 56 so that the radio frequency source 30 no longer powers the copper filaments. 14 and 17 so that the heat stops around the active segment 40. The practitioner can check that the radiofrequency source 30 no longer emits a signal by noting that the indicator light 57 is off.

[00115] Thanks to the device 1 of the present invention, the practitioner can unlock the pressure button 60, remove the distal end 1b of the elongated tubular applicator 10 from the entrance to the first fallopian tube on the left TFG, pivot the hysteroscope 80 from left to right (see Figure 13) and turn the wheel 51 in the opposite direction, namely clockwise, so as to curve the distal end 1b in the opposite direction (towards the right therefore) before inserting said distal end 1b into the entrance (intramyometrial portion) of the right fallopian tube TFD. The practitioner can then perform the same gesture as for the first fallopian tube, namely block the curvature of the distal end 1b of the tubular applicator 10 by pressing the pressure button 60, trigger the bipolar radio frequency source 30 by pressing on the switch button 56 to send an electric current into the copper filaments 14 and 17, which will have the effect of creating locally at the level of the active segment 40 an increase in temperature (>60° G) which will cause destruction by effect thermal (burn) of the tissues of the mucosa of said second right fallopian tube TFD over a small thickness. The indicator light 57 also remains lit throughout this phase to indicate to the practitioner that the radiofrequency source 30 is active.

[00116] According to a variant, after having acted on the left fallopian tube TFG, the practitioner can move the tubular applicator 10 back inside the hysteroscope 80 to bring the entire distal end 1b into sound of the working channel, reposition the hysteroscope in front of the second Fallopian tube TFD (figure 13) by tilting it from left to right (figure 13) before bringing out the distal end 1b of said tubular applicator 10 in order to give it the reverse curvature by acting on the notched wheel 51.

[00117] According to another alternative use, the practitioner can, after removing the curved distal end 1b from the entrance to the fallopian tube left TFG, turn the hysteroscope 80 and device 1 assembly 180° around its main axis in a simple gesture, and penetrate the distal end 1b, kept curved outside the hysteroscope 80, inside the entrance of the right fallopian tube TFD, always keeping the hysteroscope 80 inserted in the patient's body. This is made possible because the pressure button 60 remains active and maintains the curvature of the distal end 1b of the elongated tubular applicator 10.

[00118] In all cases, the practitioner does not need to remove the assembly consisting of the hysteroscope 80 and the medical device 1 from the patient's uterus U to pass from a fallopian tube to the other. Thus, as indicated previously, the practitioner can, in a single gynecological procedure, treat the second TFD fallopian tube in the same way as the first during a single, rapid and effective intervention.

[00119] It will be verified approximately 3 months after the operation that intra-myometrial coagulation has taken place and that the fallopian tubes are perfectly blocked, without after-effects.

[00120] Thus, the present solution does not require general anesthesia and an operating room, which considerably reduces the inconveniences, the costs incurred and the duration of the intervention. It does not cause tissue trauma because it does not require the use of trocars. Access is via natural routes (hysteroscope referenced 80 in Figures 12 and 13) and there is no risk of migration of a micro insert implanted in the tube since the device leaves no foreign bodies in the tube. patient's body. Finally, there is no phenomenon of re-waterproofing of the tubes.

[00121] The invention is thus the first device offering definitive tubal obstruction by thermofusion with a bipolar energy source limiting the risks for the patient. This device has the advantage of not leaving any foreign body in the tissues of the uterus after completion of the thermofusion because the medical device is removed in its entirety. The device thus designed can be used easily, by a single operator, quickly, efficiently and with a reproducible gesture. [00122] The device also has the advantage of offering an inert treatment, not requiring the long-term use of hormones to ensure contraception. It meets a significant demand from patients since at present there is no alternative to general anesthesia and laparoscopy. This device concerns a large market estimated at 650,000 definitive sterilizations in Europe, 900,000 cases in North America and more than 12 million for the rest of the world (Asia and Latin America).

[00123] According to an alternative embodiment illustrated in Figures 15 to 17, the medical device 1 can comprise, at its incurvable distal end 1b, a stop means 90 fixing the longitudinal position of the active radiofrequency emission segment 40 once the The distal end 1b of the elongated tubular applicator 10 implanted in the entrance (intramyometrial portion) of the fallopian tube at the desired position.

[00124] As illustrated in Figure 15, this stop means 90 takes for example the form of an inflatable balloon 91 mounted around the tubular applicator 10 (a priori before the opaque radio indicator 18).

[00125] Thus, when the elongated tubular applicator 10 is introduced into the first right or left tube, and once the curvature is defined and the distal end 1b placed in the desired position, the balloon 91 is inflated (air passage inside the tubular applicator for example), which makes it possible to maintain the distal end 1b in position in the tube, and in particular the active radiofrequency emission segment 40 which must be placed as precisely as possible to irradiate the chosen areas. According to a variant, the balloon is already in a naturally inflated state, which avoids an inflation step.

[00126] In a second step, the bipolar radio frequency source is actuated using the switch button 56 of the handling handle 20 so as to emit a radio frequency signal which will burn the surrounding tissue to a small thickness, as described previously. in relation to figures 12 and 13.

[00127] During a third step, the elongated tubular applicator 10 equipped with its inflated balloon 91 is removed from the entrance to the tube. Fallopian and second fallopian tube can be treated as previously described.

[00128] Finally, in a fourth step, the tubular applicator 10 and the hysteroscope are completely removed from the uterus.

[00129] According to another alternative embodiment illustrated by Figures 16 and 17, the stop means 90 takes the form of a stent 92 expandable radially in the manner of an umbrella mounted around the tubular applicator 10 (a a priori before the opaque radio indicator 18) and whose operation is similar to the balloon described previously.

[00130] Thus, when the elongated tubular applicator 10 is introduced into the first tube, and once the curvature of the distal end 1b is defined, the stent 92 is opened radially (FIG. 17), which allows to maintain the distal end 1b in position in the tube, and in particular the active radiofrequency emission segment 40 which must be placed as precisely as possible to irradiate the chosen areas. The stent 92 is folded radially (Figure 16) to return to its initial position once the first tube has been treated in order to treat the second, or it is folded once both tubes have been treated, so as to be able to easily remove it from the uterus. of the patient the assembly consisting of the hysteroscope 80 and the tubular applicator 10.

[00131] It should be clearly understood that the detailed description of the subject of the invention, given solely by way of illustration, does not in any way constitute a limitation, technical equivalents also being included in the scope of the present invention. .

[00132] Thus, it could be possible to provide only one cable wound around an axis of rotation of the movable wheel and which, by traction in one direction or another, would curve the distal end of the tubular applicator 10.

[00133] The wheel can take another shape, or even be replaced by another means of pulling the cables.

Claims

Claims Claim 1. Single-use gynecological medical device (1) intended to produce thermal lesions in the fallopian tubes (TFG, TFD) by application of bipolar radiofrequency to create definitive tubal sterilization, said device (1) comprising a slender tubular applicator (10) made of flexible material extending along a longitudinal axis (XX') and equipped with a handle-type manual gripping means (20) arranged near a proximal end (la) and an active segment ( 40) of bipolar radio frequency emission arranged near a distal end (1b), said active radio frequency emission segment (40) being connected to a radio frequency source (30), the manual gripping means (20) comprising at least: - a mechanical curving actuator (50) movable manually for bending the distal end (1b) of the elongated tubular applicator (10) and in the form of a traction wheel (50) which can be rotated in two opposite directions of rotation around a pivot (55), and - a means (60) for blocking said curvature once it has been determined using said mechanical curvature actuator (50), - the elongated tubular applicator (10) containing at least two identical parallel cables (58, 59) fixed on the one hand in the immediate vicinity of its distal end (1b) and on the other hand at two opposite fixing points of the traction wheel (51), the cables (58, 59) being able to slide over a distance of a few millimeters inside the elongated tubular applicator (10), the rotation in one direction of said traction wheel (51) causing a traction of a first cable (58; 59) resulting in a curvature in a first direction of the distal end (1b) of the elongated tubular applicator (10) as the wheel (51) is rotated , and the rotation in the opposite direction of said traction wheel (51) causing traction of the second cable (59; 58) resulting in a curvature in a second opposite direction of the distal end (1b) of the applicator elongated tubular (10) as said wheel (51) is turned, characterized in that: - the elongated tubular applicator (10) is crossed longitudinally by at least two separate conductive filaments (14, 17) respectively forming their distal ends (14b, 17b) two radio frequency electrodes (13, 16) spaced axially from each other and arranged in the active radio frequency emission segment (40), an electrical insulating segment (15) being arranged between the two radio frequency electrodes (13, 16), - the distal end (1b) of the elongated tubular applicator (10) has an atraumatic round tip (11), and - the distal ends (58b, 59b) of the cables (58, 59) are axially arranged closer to the atraumatic tip (11) than the distal ends (14b, 17b) of the conductive filaments (14, 17) forming points of fixing the latter. Claim 2. Device (1) according to claim 1, characterized in that the elongated tubular applicator (10) comprises a bendable zone having a length of between approximately 2 and 10 centimeters from its distal end (1b), of preferably between approximately 4 and 8 centimeters. Claim 3. Device (1) according to any one of the preceding claims, characterized in that the maximum angle of curvature formed between the longitudinal axis (XX') of the elongated tubular applicator (10) and a tangent ( T) at its distal end (1b) is between approximately 30° and 90 O Claim 4. Device (1) according to any one of the preceding claims, characterized in that the curvature blocking means (60) is a press button linked to the curvature actuator (50). Claim 5. Device (1) according to any one of the preceding claims, characterized in that the elongated tubular applicator (10) comprises, from its distal end (1b), an active radiofrequency emission segment (40). ) measuring between approximately 4 and 10 millimeters and preferably between approximately 6 and 8 millimeters. Claim 6. Device (1) according to any one of the preceding claims, characterized in that each radiofrequency electrode (13, 16) has an axial length of between approximately 2 and 4 millimeters and preferably approximately equal to 3 millimeters. Claim 7. Device (1) according to any one of the preceding claims, characterized in that the insulating segment (15) has an axial length approximately equal to 1 millimeter. Claim 8. Device (1) according to any one of the preceding claims, characterized in that the elongated tubular applicator (10) comprises a mark (18) opaque to X-rays placed upstream of the active radiofrequency emission segment ( 40). Claim 9. Device (1) according to any one of the preceding claims, characterized in that the manual gripping means (20) is equipped with an indicator light (57) indicating the operation of the radio frequency source. Claim 10. Device (1) according to any one of the preceding claims, characterized in that the manual gripping means (20) is equipped with a button (56) for activating/deactivating the radio frequency source (30). Claim 11. Device (1) according to any one of the preceding claims, characterized in that the manual gripping means (20) contains the radio frequency source (30) and a battery (90) for powering the radio frequency source (30). ). Claim 12. Device (1) according to any one of the preceding claims, characterized in that it further comprises a stop means (90) fixing the longitudinal position of the active radio frequency emission segment (40) once the distal end of the tubular applicator (10) implanted in the fallopian tube at the desired position. Claim 13. Device according to claim 12, characterized in that the stop means (90) is an inflatable balloon (91) mounted around the tubular applicator (10). Claim 14. Device according to claim 12, characterized in that the abutment means (90) is a stent (92) mounted in a substantially cylindrical sheath surrounding the tubular applicator (10), said stent being radially deployable in the manner of an umbrella to form a cone narrowing as one approaches the active radio frequency emission segment (40). Claim 15. Assembly comprising a device (1) according to any one of the preceding claims and a hysteroscope (80) inside which the tubular applicator (10) is inserted and slides axially.